Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
6.25
+0.26 (4.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Design Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
353.88M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | 226.00K | -608.00K | -72.90% |
Dec 31, 2019 | 834.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AngioDynamics | 292.73M |
Valneva SE | 176.82M |
Kamada | 158.38M |
Spok Holdings | 137.71M |
NeuroPace | 76.45M |
Aquestive Therapeutics | 58.90M |
Absci | 4.21M |
Prime Medicine | 800.00K |
DSGN News
- 5 weeks ago - Design Therapeutics to Participate in Multiple Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio - GlobeNewsWire
- 4 months ago - Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio - GlobeNewsWire
- 8 months ago - Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones - GlobeNewsWire
- 8 months ago - Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference - GlobeNewsWire
- 9 months ago - Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript - Seeking Alpha
- 9 months ago - Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 10 months ago - Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update - GlobeNewsWire